Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 10:16 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1969–1992 of 14,141 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Safety Control Clear all

Conditions: Antibiotic Prophylaxis Surgery
Interventions: CeFAZolin 1000 MG, Saline (0.9%, sterile, for infusion); Drug
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Somerset, New Jersey

Conditions: Painful Diabetic Neuropathies
Interventions: Low Dose: 16 mg Engensis (VM202), High Dose: 32 mg Engensis (VM202), Control- Placebo (normal saline); Biological · Other
Lead sponsor: Helixmith Co., Ltd.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 13
States / cities: Walnut Creek, California • Orlando, Florida • Palm Beach Gardens, Florida + 9 more

Conditions: Asthma
Interventions: IPL512,602 20 mg once daily, IPL512,602 Matching Placebo once daily; Drug
Lead sponsor: Inflazyme Pharmaceuticals Ltd; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 8
States / cities: Long Beach, California • Los Angeles, California • San Diego, California + 5 more

Conditions: Schizophrenia
Interventions: SEP-363856 50mg, SEP-363856 75mg, Placebo; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 13 Years to 65 Years
Enrollment: 463 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 18
States / cities: Little Rock, Arkansas • Anaheim, California • Bellflower, California + 13 more

Conditions: Moderate-severe Pain
Interventions: Ages 7-11, ages 12-17; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 7 Years to 17 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 19
States / cities: Irvine, California • Los Angeles, California • Orange, California + 5 more

Conditions: Atopic Dermatitis
Interventions: Tralokinumab, Placebo; Drug
Lead sponsor: LEO Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 380 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 21
States / cities: Birmingham, Alabama • Encinitas, California • Fountain Valley, California + 17 more

Conditions: Narcolepsy, Excessive Daytime Sleepiness, Cataplexy Narcolepsy
Interventions: mazindol extended release, Placebo; Drug
Lead sponsor: NLS Pharmaceutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 22
States / cities: Birmingham, Alabama • Redwood City, California • San Diego, California + 17 more

Conditions: Stroke, Stroke, Acute, Stroke, Ischemic
Interventions: AER-271, Placebo; Drug
Lead sponsor: Aeromics, Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Diabetic Macular Edema
Interventions: Faricimab, Ranibizumab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 229 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 60
States / cities: Phoenix, Arizona • Tucson, Arizona • Fullerton, California + 53 more

Conditions: Benign Prostatic Hyperplasia
Interventions: ALFUZOSIN; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 50 Years and older · Male only
Enrollment: 372 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Neuropathic Pain
Interventions: BMS-741672, Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 8
States / cities: Tustin, California • Palm Beach Gardens, Florida • St. Petersburg, Florida + 5 more

Conditions: Healthy Volunteers
Interventions: ABT-102, Placebo; Drug
Lead sponsor: Abbott; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2009
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Tourette Syndrome
Interventions: NBI-98854, Placebo; Drug
Lead sponsor: Neurocrine Biosciences; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 44
States / cities: Sun City, Arizona • Springdale, Arkansas • Long Beach, California + 41 more

Conditions: COVID-19
Interventions: ensovibep, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 407 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 27
States / cities: Jasper, Alabama • Colton, California • Fullerton, California + 21 more

Conditions: Attention-Deficit/Hyperactivity Disorder
Interventions: TAK-137, TAK-137 Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 1
States / cities: Marlton, New York

Conditions: COPD
Interventions: QBM076, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 35 Years to 75 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Healthy Participants
Interventions: AZD4916, Placebo; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 160 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Glendale, California

Conditions: Rheumatoid Arthritis
Interventions: MM-093; Drug
Lead sponsor: Merrimack Pharmaceuticals; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 20
States / cities: Montgomery, Alabama • Gilbert, Arizona • Scottsdale, Arizona + 16 more

Conditions: Healthy
Interventions: YUQ-A1007 is a novel gut-enriched AhR agonist. This compound is undergoing preclinical development, and comprehensive nonclinical studies.; Drug
Lead sponsor: Allianthera (Suzhou) Biopharmaceuticals Co., Ltd.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 47 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Anaheim, California

Conditions: Psoriatic Arthritis
Interventions: Zasocitinib, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 601 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 22
States / cities: Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 19 more

Conditions: CKD, Metabolic Acidosis
Interventions: Veverimer, Placebo; Drug
Lead sponsor: Renibus Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 28
States / cities: Chula Vista, California • Los Angeles, California • Sacramento, California + 25 more

Conditions: Prostate Cancer, Prostate Cancer (Diagnosis), High-risk Prostate Cancer, Localized Prostate Carcinoma, Very High Risk Prostate Carcinoma
Interventions: 177 Lutetium Prostate-Specific Membrane Antigen 617, Actinium-225 Prostate-Specific Membrane Antigen 617, Non-investigational, Prostatectomy, Prostate Tissue Collection, Single-photon emission computed tomography (SPECT)/Computerized tomography (CT), Blood Sample Collection; Drug · Procedure
Lead sponsor: Thomas Hope; Other
Eligibility: 18 Years and older · Male only
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Autosomal Dominant Polycystic Kidney Disease
Interventions: Tolvaptan MR, Tolvaptan IR, Placebo; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 178 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 35
States / cities: Huntsville, Alabama • Mobile, Alabama • Peoria, Arizona + 31 more

Conditions: Androgenetic Alopecia, Hair Loss, Female Pattern Baldness
Interventions: HairMax LaserComb, Control Device; Device
Lead sponsor: Lexington International, LLC; Industry
Eligibility: 25 Years to 60 Years · Female only
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 5
States / cities: Miami, Florida • Palm Beach, Florida • Hackensack, New Jersey + 2 more

Search by objective public record fields.

Efficacy and Safety of Intraosseous Antibiotic Prophylaxis in Total Hip Replacement

Safety and Efficacy Study for the Treatment of Painful Diabetic Neuropathy

Control of Asthma Patients Symptomatic on Inhaled Corticosteroids

A Clinical Trial to Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia

Safety and Pharmacokinetic Study of EMBEDA in Children Ages 7-17 With Pain

Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3

Four-week Study of the Safety and Efficacy of NLS-2 (Mazindol Extended Release) in the Treatment of Narcolepsy

Phase 1 Study to Assess AER-271

A Study of Faricimab (RO6867461) in Participants With Center-Involving Diabetic Macular Edema

The Efficacy, Onset of Effect, and Safety of Alfuzosin Once Daily in the Treatment of Lower Urinary Tract Symptoms of Benign Prostatic Hyperplasia: A Randomized, Placebo-Controlled Trial Using an Acute International Prostate Score

BMS-741672 for Diabetic Neuropathic Pain

A Safety, Tolerability and Pharmacokinetic Study of ABT-102 in Healthy Subjects

Safety and Efficacy Study of NBI-98854 in Children and Adolescents With Tourette Syndrome

A Dose Finding, Efficacy and Safety Study of Ensovibep (MP0420) in Ambulatory Adult Patients With Symptomatic COVID-19

Safety, Tolerability, and Pharmacokinetics of Multiple Rising Doses of TAK-137 in Adults With Attention-Deficit/Hyperactivity Disorder.

A Safety, Tolerability and Efficacy Study in Chronic Obstructive Pulmonary Disease (COPD) Patients With QBM076.

A Study to Investigate the Safety and Pharmacokinetics of Single- and Multiple-ascending Doses of AZD4916 in Healthy Volunteers

A Phase 2 Study to Evaluate the Efficacy and Safety of 60mg of MM-093 in Patients With Active Rheumatoid Arthritis

A Study of Oral YUQ-A1007 in Healthy Volunteers

A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines

A Study to Evaluate the Efficacy and Safety of Veverimer for the Treatment of Metabolic Acidosis

Comparison of 177Lu-PSMA-617 and 225Ac-PSMA-617

8-Week Study of Tolvaptan Dose Forms in Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Treatment of Androgenetic Alopecia in Females, 9 Beam